Rising prevalence of breast cancers globally is soaring the global breast cancer drugs market size. As per the World Health Organization, in 2018, breast cancer had the largest number of new cancer incidences. In 2018, the reported number of new breast cancer incidences were 234,087, which accounted for 11% of all new cancer incidences. As of January 2019, there were 16.9 million survivors in the US, which is expected to reach 21.7 million by 2029 (National Cancer Institute). Radiation therapy is one of the primarily used treatments for cancer. It can be given to cure cancer, either alone or in combination with surgery and/or chemotherapy. Breast, lung, and prostate cancer patients consist of over half of all patients receiving radiation therapy.
Browse the full report description Global Breast Cancer Drugs Market Size, Share & Trends Analysis Report by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Forecast 2019-2025 at https://www.omrglobal.com/industry-reports/breast-cancer-drugs-market
Increasing FDA approvals for personalized medicine is further promising ample growth opportunities for the market
The increasing adoption of personalized medicines for cancer treatment is furthermore augmenting the growth of the breast cancer drugs market. Increasing FDA approvals for personalized medicines are supporting to drive the growth of the market in the region. For instance, as per the Personalized Medicine Coalition, in 2018, 25 of the 59 new molecular entities (NMEs) FDA approved are personalized medicines, which is 42% of all new drug approvals. The coalition classified 34% of NMEs as personalized medicines in 2017, 28% in 2015; 27% in 2016. A significant number of cancer precision medicines approved in 2018, which includes biosimilars, Truxima (rituximab-abbs) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma (NHL), and Herzuma (trastuzumab-pkrb), as a biosimilar to Herceptin for the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer.
Asia-Pacific to gain maximum traction over the forecast period
Asia-Pacific is expected to witness the fastest growth rate in the global breast cancer industry over the forecast period. Increasing prevalence of breast cancer coupled with the improving healthcare infrastructure is influencing the regional market growth. The increasing number of breast cancer patients reflects the need for the therapies including drugs for the treatment of breast cancer. As per American Cancer Society, breast cancer, lung and bronchus cancer, stomach cancer, colorectum cancer, and esophagus cancer are the most common cancer diagnosed in women, accounting for around 60% of all cases in China. Moreover, 15% of all new cancer incidences in women accounted for breast cancer, making it the most severe health condition for women in China.
Further, according to the Indian Council of Medical Research, around 1.7 million new cases of cancer are expected to emerge that are projected to take over 800,000 lives by 2020. The major mortalities in India is due to cancer which constitutes to Lung and oral among males and breast and cervix in females. Breast cancer in females accounts for more than 50% of all cancer deaths in India. Breast cancer is most prevalent in women with oral cancer being more common in males. The north-eastern states of India reported the maximum number of cancer cases. As per National Institute of Cancer Prevention and Research (NICPR), the breast cancer cases reported in India accounted to 10% of all cancers that was around 150,000 new incidences in 2016,
Current Market Trends Covered in the Global Breast Cancer Drugs Market Report
Global Breast Cancer Drugs Market Segmentation
By Drug Class Type
Global Breast Cancer Drugs Market – Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To
learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/breast-cancer-drugs-market